New study backs oral agmatine for neuropathic pain

New study backs oral agmatine for neuropathic pain

Results indicate that agmatine sulfate significantly decreases burning, tingling and other unpleasant aspects of neuropathic pain.

Gilad&Gilad is proud to announce that a clinical study substantiating the effectiveness of oral agmatine for neuropathic pain will be presented at the  American Academy of Neurology (AAN) 66th Annual Meeting on May 1, 2014, in Philadelphia.

Clinical investigators from JFK Medical Center Neuroscience Institute working in collaboration with company scientists will present new findings from an ongoing case series study indicating the effectiveness of agmatine sulfate on neuropathic pain in small fiber neuropathy (, Registry Identifier: NCT01524666). The findings will be presented on Thursday afternoon, May 1, 2014, during Poster Session VII, Poster #: P7.094.
Results from 10 patients who have already completed this ongoing case series study indicate that agmatine sulfate, has significant effects in decreasing burning, tingling and unpleasant aspects of neuropathic pain. Small-fiber neuropathy is associated with neuropathies of various causes (e.g., diabetic neuropathy, chemotherapy-induced neuropathy and idiopathic neuropathy) leading to damage of thin nerve fibers. The study thus, affirms the general beneficial effects of agmatine in the various types of neuropathy.
It is estimated that more than 20 million people in the U.S. alone suffer from neuropathies, but their need for an effective treatment remains unmet. The present findings, therefore, have wide implications for millions of people worldwide.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.